NCT04558359View on ClinicalTrials.gov

Renin and Renal Biomarker Response to Angiotensin II

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

July 24, 2023

Study Completion Date

July 30, 2023

Conditions
Septic ShockAcute Kidney Injury
Interventions
OTHER

Standard of Care

These patients will receive standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.

DRUG

Angiotensin II

These patients will receive angiotensin II in addition to standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.

Trial Locations (1)

40536

University of Kentucky HealthCare Chandler Medical Center, Lexington

All Listed Sponsors
lead

Alexander Flannery

OTHER

NCT04558359 - Renin and Renal Biomarker Response to Angiotensin II | Biotech Hunter | Biotech Hunter